PedAM
Pediatric Disease Annotations & Medicines
| Disease | multiple sclerosis |
| Phenotype | C0023524|progressive multifocal leukoencephalopathy |
| Sentences | 22 |
| PubMedID- 22054236 | Background and purpose: temporary discontinuation of natalizumab is sometimes considered as the observed risk of progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms). |
| PubMedID- 21576685 | Objective: natalizumab, a therapy for multiple sclerosis (ms), has been associated with progressive multifocal leukoencephalopathy (pml), a rare opportunistic infection of the cns associated with the jc virus. |
| PubMedID- 24242357 | Objective: to identify cases of laboratory- or biopsy-confirmed progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms) who previously discontinued natalizumab (ntz) for reasons unrelated to suspected or proven pml and assess pml risk factors in these cases. |
| PubMedID- 22585288 | Natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis (ms) occurred in two individuals also treated with interferon beta1a, raising concerns about the interaction of these disease-modifying agents and leading to the recommendation to avoid their concomitant administration. |
| PubMedID- 23493158 | progressive multifocal leukoencephalopathy in patients with multiple sclerosis. |
| PubMedID- 25908254 | Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. |
| PubMedID- 25698174 | Objective: the objective of this paper is to estimate the risk of reaching well-established disability milestones after withdrawal of natalizumab (ntz) due to concern about the risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis (ms). |
| PubMedID- 26394704 | Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. |
| PubMedID- 24614671 | Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis. |
| PubMedID- 24128680 | Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study. |
| PubMedID- 20298967 | Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. |
| PubMedID- 24136456 | progressive multifocal leukoencephalopathy in multiple sclerosis. |
| PubMedID- 24664166 | Importance: infection with jc virus (jcv) may lead to development of demyelinating progressive multifocal leukoencephalopathy in patients with multiple sclerosis (ms) who are treated with natalizumab. |
| PubMedID- 26190565 | Due to an association of the anti-integrin agent natalizumab with progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms), a newly developed anti-jcv antibody assay has been implemented as a risk-stratification tool for natalizumab-treated patients with ms. |
| PubMedID- 23338729 | Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. |
| PubMedID- 24367037 | We report two cases of multiple sclerosis (ms) patients with natalizumab-associated progressive multifocal leukoencephalopathy. |
| PubMedID- 25205744 | Objective: to investigate the mri manifestation pattern of asymptomatic natalizumab-associated progressive multifocal leukoencephalopathy (pml) in patients with multiple sclerosis (ms). |
| PubMedID- 23323645 | Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy. |
| PubMedID- 24852919 | Blood mirna expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. |
| PubMedID- 22057786 | Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. |
| PubMedID- 20442571 | Recent findings: natalizumab, a mab targeting the alpha-4 integrins, which is efficient in relapsing-remitting multiple sclerosis, has been associated with progressive multifocal leukoencephalopathy (pml). |
| PubMedID- 24341880 | Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy. |
Page: 1